Test Price
2,800 AEDโ Home Collection Available
PPARG Gene Lipodystrophy, Familial Partial, Type 3 Genetic Test in Dubai & UAE
Executive Summary & Core Metrics
This precise genetic test diagnoses Familial Partial Lipodystrophy Type 3 (FPLD3) via Next Generation Sequencing (NGS) of the PPARG gene, guaranteeing 99.9% diagnostic sensitivity in strict adherence to ISO 9001:2015 standards. Our integrated molecular service includes VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection for verified whole blood or DNA FTA card specimens.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM to 11 PM).
- Clinical Guidance: Dedicated telephonic post-test consultation for result interpretation and metabolic risk stratification.
- Insurance: Direct billing verification available via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The PPARG gene NGS test detects pathogenic variants responsible for FPLD3, a rare metabolic disorder characterized by abnormal subcutaneous fat distribution and severe insulin resistance. Unlike limited single-variant genotyping, our comprehensive sequencing approach provides definitive molecular diagnosis, informs metreleptin therapy eligibility, and enables accurate familial cascade screening.
| Feature | DNA Labs UAE NGS Full Gene Test | Standard Alternative (Single-Variant Genotyping) |
|---|---|---|
| Precision | Comprehensive gene coverage; >99.9% analytical sensitivity | Limited to known mutations; may miss novel pathogenic variants |
| Method | Next Generation Sequencing (NGS) of entire PPARG coding region | Sanger sequencing or allele-specific PCR |
| Turnaround Time | 3 to 4 Weeks | 2 to 3 Weeks (limited scope) |
Physician Insight & Safety Protocols
โAs a Consultant Medical Geneticist, I emphasize that PPARG sequencing results must be integrated with the patientโs full clinical phenotype, including metabolic indices and adiposity distribution. A confirmed pathogenic variant establishes the diagnosis of FPLD3 and guides targeted therapy. However, a negative result does not exclude other genetic lipodystrophies; longitudinal clinical follow-up remains the cornerstone of management.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA ID: 9294403)
Important Medical Advisory
Do not discontinue prescribed metabolic or endocrine medications without consulting your physician. Genetic test results provide predictive and diagnostic insights, but must be correlated with liver function, renal panels, and glycemic control under strict medical supervision.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Individuals requiring urgent hospitalization, those unable to provide informed consent (guardian required for minors per Federal Law No. 2 of 2019), or patients with active hemolysis compromising DNA extraction quality.
- Emergency Red Flags: If you experience acute pancreatitis symptoms (severe abdominal pain, vomiting), diabetic ketoacidosis, or rapid unexplained weight loss, seek immediate emergency care. Do not delay urgent treatment while awaiting genetic test results.
Patient FAQ & Clinical Guidance
1. What is the PPARG gene test for familial partial lipodystrophy type 3?
This test sequences the PPARG gene to identify pathogenic variants causative of Familial Partial Lipodystrophy Type 3, a rare metabolic disorder. It provides a definitive molecular diagnosis, guides treatment eligibility for therapies such as metreleptin, and enables accurate family cascade screening for at-risk relatives.
2. How is the sample collected?
A certified phlebotomist collects a standard peripheral whole blood sample (EDTA tube) or accepts a DNA FTA card. Our VIP Mobile Phlebotomy service operates daily from 8 AM to 11 PM, utilizing strict temperature-controlled cold-chain logistics to ensure complete sample integrity from collection to laboratory processing.
3. What is the turnaround time and total cost?
Results are delivered within 3 to 4 weeks from sample receipt. The total cost is 2800 AED, inclusive of the comprehensive NGS analysis, genetic counseling, and post-test clinical guidance. Direct insurance billing verification is available immediately via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Your genetic data is handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your information is encrypted, anonymized for diagnostic accuracy, and never shared with third parties without explicit consent.
Clinical & Logistical Metadata
| Test Name | PPARG Gene Lipodystrophy, Familial Partial, Type 3 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or DNA FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) โ Full Gene Coverage |
| ICD-10-CM Code | E88.1 |
| LOINC Code | 81315-3 |
| DHA Facility License & Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians